<DOC>
	<DOCNO>NCT00988078</DOCNO>
	<brief_summary>The polycystic ovary syndrome common endocrinopathy reproductive age woman . The pathophysiology syndrome remain unclear , evidence decrease insulin sensitivity may relate syndrome . There study show action factor sensitivity insulin receptor , melatonin . It hormone produce pineal gland , whose role still uncertain human reproduction , although many study find may relate sex hormone effect . Many patient polycystic ovary syndrome ( PCOS ) may hyperinsulinemia , pinealectomized rat determine hypoglycemia hyperinsulinemia , reduce release insulin response glucose . Therefore , suppose blood level melatonin might correlate blood insulin concentration patient syndrome . Moreover , insulin sensitize agent use treatment patient insulin resistance PCOS , base main pathophysiological substrate hyperinsulinemia . In fact , metformin use literature . However , study use metformin adolescent . The evidence drug group patient show good therapeutic response side effect . The objective study evaluate effect metformin insulin resistance level melatonin adolescent PCOS . It perform prospective , randomize , double-blind placebo-controlled study 90 adolescent PCOS . It evaluate clinical laboratory parameter ( TSH , free T4 , prolactin , FSH , LH , estradiol , total testosterone , androstenedione , DHEA-s , 17-OH progesterone , SHBG , free androgen index , index HOMA-IR QUICKI fast glucose insulin , total cholesterol fraction , triglyceride , creatinine , AST ALT creatinkinase , fibrinogen PAI-1 , melatonin 6 month treatment .</brief_summary>
	<brief_title>Effects Metformin Oral Hormonal Contraceptive Adolescents With Polycystic Ovary Syndrome</brief_title>
	<detailed_description>Design : 90 patient select prospective , randomize double-blinded study . They assign two group : A ) 45 patient , treat OC ( oral contraceptive ) metformin 1500mg/ day . B ) 45 patient , treat OC placebo . The length treatment six month . Inclusion criterion : patient 19 years-old , least 2 year menarche , Polycystic Ovary Syndrome base Rotterdan criterion . Exclusion criterion : patient Diabetes Mellitus , hypertension , hyperprolactinemia , adrenal enzymatic deficiency , Cushing syndrome , thyroidopathy , renal hepatic disfunction , use OC insulin-sensitising drug last 90 day , pregnancy , androgen tumor , hormonal-sensitive tumor past , contra-indication medication use study . Clinical parameter include weight height ( BMI ) , waist hip ratio , habit like smoke drinking , drug addiction , blood pressure measurement , hirsutism acne . Laboratorial parameter include TSH , free T4 , prolactin , FSH , LH , estradiol , total testosterone , androstenedione , s-DHEA , 17-OH progesterone , SHBG , free androgen index , fast glucose insulin , total cholesterol fraction , triglyceride , creatinin , TGO , TGP , CK , PAI-1 , fibrinogen , melatonin . Patients evaluate use parameter begin , 1 , 3 6 month use drug .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Patients 19 yearsold , least 2 year menarche Patients Polycystic Ovary Syndrome base Rotterdan criteries Patients Diabetes Mellitus , hypertension , hyperprolactinemia , adrenal enzymatic deficiency , Cushing syndrome , thyroidopathy , renal hepatic disfunction Use OC insulinsensitising drug last 90 day Pregnancy Androgen tumor , hormonalsensitive tumor past Contraindication medication use study</criteria>
	<gender>Female</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>metformin</keyword>
	<keyword>Hyperandrogenism</keyword>
	<keyword>Metabolic Syndrome X</keyword>
	<keyword>adolescent</keyword>
	<keyword>melatonin</keyword>
	<keyword>Polycystic Ovary Syndrome</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Menstrual Cycle</keyword>
</DOC>